Abstract 13236: Low Body Weight is Significantly Associated with the Incidence of Stroke in Atrial Fibrillation Patients
Introduction: Atrial fibrillation (AF) increases the risk of stroke. Oral anticoagulants (OAC) are effective for the prevention of stroke, but bleeding complications are more often observed in patients with low body weight. The Japanese patients with AF are generally small and lean, and data regarding those with low body weight (≤50 kg) are very limited.
Methods: The Fushimi AF Registry is a community-based prospective survey of AF patients in Fushimi-ku, Japan. We aimed to enroll all of the AF patients in Fushimi-ku. One-year follow-up was completed in 3,189 patients, and body weight data was available in 2,842 patients. We compared the backgrounds and incidences of clinical events during one-year follow-up between those with low body weight ≤50 kg (LBW) and those without it (non-LBW).
Results: Patients with LBW accounted for 26.7% (759 patients) of all the patients. LBW group was more often female (LBW 77.9% vs. non-LBW 25.9%; p<0.01), older (79.4 ± 9.9 vs. 71.8 ± 10.2 years; p<0.01), had higher CHADS2 score (2.29 ± 1.33 vs. 2.01 ± 1.32; p<0.01) and received lower OAC prescription (47.0% vs. 56.0%; p<0.01). During one-year follow-up, incidence of stroke or systemic embolism was higher in LBW (4.4% vs. 2.1%; p<0.01), whereas that of major bleeding was comparable (2.1% vs. 1.7%; p=0.50). The Kaplan-Meier curves for the incidence of stroke or systemic embolism and major bleeding are shown in the Figure. This trend was also the case both in the subgroups stratified by sex or OAC prescription. Even after adjustment by the components of CHADS2 score and OAC prescription, LBW was independently associated with the incidence of stroke or systemic embolism during one-year follow-up (hazard ratio; 1.70, 95% confidence interval: 1.05-2.77, p=0.03)
Conclusions: Many of Japanese AF patients have low body weight. They generally have high risk profile for stroke, and indeed showed higher incidence of stroke during one-year follow-up, whereas that of major bleeding was not particularly high.
Author Disclosures: Y. Hamatani: None. H. Ogawa: None. M. Iguchi: None. Y. Yamashita: None. M. Esato: None. Y. Chun: None. H. Wada: None. K. Hasegawa: None. M. Abe: None. M. Akao: Research Grant; Modest; Bayer Healthcare, Daiichi-Sankyo, Sanofi-Aventis, Takeda Pharmaceutical. Research Grant; Significant; Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb. Honoraria; Modest; Boehringer Ingelheim. Honoraria; Significant; Bristol-Myers Squibb, Pfizer, Bayer Healthcare.
- © 2014 by American Heart Association, Inc.